Business Daily from THE HINDU group of publications
Friday, Sep 01, 2006

Cross Currency

Group Sites

Corporate - Mergers & Acquisitions
Kemwell completes Pfizer's Swedish plant acquisition

Our Bureau

Deal expected to add Rs 200 cr to Kemwell's turnover

Bangalore , Aug. 31

Bangalore-based pharmaceutical company Kemwell has said it has completed the acquisition of Pfizer's Swedish manufacturing plant.

The deal for the Uppsala plant was closed on August 28, concluding the agreements signed in February 2006. The unit, the first Indian pharma acquisition in Sweden, was handed over to Kemwell's management, Kemwell Pvt Ltd said in a release here.

USFDA approved

The USFDA-approved Uppsala facility makes drug actives and finished drugs. It is expected to add Rs 200 crore to Kemwell's annual turnover, besides giving it access to technology, European quality standards and help enlarge its contract manufacturing activities.

Mr Perake Oldentoft, board member and Swedish resident, will be the Managing Director of the 170-strong Kemwell AB; the current organisational structure is to be maintained. It will continue to contract-manufacture its main product, salazopyrine, for Pfizer as well as seek new customers. Salazopyrine, used to treat arthritis and irritable bowel syndrome, has an estimated global sales of $200 million.

Without disclosing the financial details, Kemwell said the acquisition was financed through internal accruals and loans from a Swedish bank.

The Bangalore parent will now use its manpower and resources to integrate the new entity with its Indian operations. The new entity supplies to the US, Europe, Japan and nearly 80 markets.

According to the Chairman & Managing Director, Mr Subhash Bagaria, "Kemwell is determined to become a global player in contract manufacturing. Through the Swedish acquisition and the new facility in India, we can not only ensure rapid growth with a major capacity addition but also apply best practices from both parts of the world."

More Stories on : Mergers & Acquisitions | Pharmaceuticals | Overseas Investments

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
The `other' Ambani

Alstom bags Laos order
Reality check on awards
Tata Motors unit wins CII-Exim Bank award
Ministry may improve selection criteria for transfer pricing audits
Shree Renuka pact for Munoli project
Oil bonds not to get SLR status, says Chidambaram
Banks reject SPIC proposals for debt revamp
Rayalaseema Hi-Strength revamps capital
P.K. Ruia acquires Monotona Tyres
Sterling Infotech buys 40 pc in Finland wind turbine co
Kemwell completes Pfizer's Swedish plant acquisition
Praj plans to acquire US engineering co
NPIL lab chain plans Rs 150-cr expansion
Gulf Gate to set up shop in NY, London
Wockhardt antibiotic gets USFDA nod
PVR Projects plans foray into hotels, realty
Tata Coffee to focus on value-added timber products
Kerala Govt to form core panel with banks to revive PSUs
Coca-Cola plans to invest $120 m in Indian arm
Agening workforce — Healthcare, retirement costs to weigh heavily on cos: Survey

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line